Lingyi Biotech

Lingyi Biotech was founded in February 2021. As a leading gene therapy company with the world's most advanced functional validation platform for rare disease animal models, Lingyi Biotech is committed to original innovation and focuses on hereditary rare diseases in metabolism, CNS, and ophthalmology. The company boasts a world-class team in the discovery, development, and industrialization of gene therapies and rare diseases. It also possesses the world’s leading platform for the production and validation of rare disease animal models, addressing the pain point of the lack of effective animal models in rare disease research. The team has deep experience and a successful background in the R&D and industrialization of hereditary rare diseases. Its current R&D pipeline includes several globally leading gene therapy projects. Lingyi Biotech concentrates on the research and development of gene therapy drugs related to metabolic, neurological, and ophthalmic hereditary rare diseases. With the support of a comprehensive rare disease model platform, an AAV gene therapy technology platform, and a production platform, Lingyi Biotech has established a rich product pipeline.